Thromb Haemost 1976; 36(03): 566-581
DOI: 10.1055/s-0038-1648077
Original Article
Schattauer GmbH

Studies on Activator Formation in Human Plasma with Streptokinase

III. Investigation of Activator Kinetics in Undiluted Plasma in Terms of Urokinase Equivalents[*]
M Martin
1   Aggertalklinik, Clinic for Vascular Diseases, Engelskirchen-Cologne, Germany
,
Technical Assistance,
Miss H Auel
1   Aggertalklinik, Clinic for Vascular Diseases, Engelskirchen-Cologne, Germany
› Author Affiliations
Further Information

Publication History

Received 12 December 1975

Accepted 28 July 1976

Publication Date:
24 July 2018 (online)

Summary

A new method is presented for estimating the activator (plasminogen-streptokinase complex) concentration in native plasma of patients undergoing streptokinase infusion. The principle of the method is based on clot lysis time as recorded by the thromboelastograph. The test clot constituents were bovine fibrinogen, bovine plasminogen, EDTA, human plasma (with unknown activator concentrations), and thrombin. In order to obtain a standardization line, urokinase dissolved in NaCl solution was substituted for patients’ plasma. Thus, each lysis time could easily be converted into urokinase equivalent (CTA-u/ml). Streptokinase and plasminogen molecules in undiluted patients’ plasma were found to exist both in an activator-bound (equimolar plasminogen-streptokinase complex) and in a freely circulating form. This result is in agreement with earlier findings where the activator complex was demonstrated to be a widely dissociated complex in highly diluted plasma of patients, thus displaying an ample proportion of free streptokinase and plasminogen molecules. Streptokinase treatment using dosage schemes of 100,000 u SK/h, 150,000 u/h, and 200,000 u/h were monitored by quantitative activator, streptokinase, and plasminogen measurements. An average activator concentration of 50–100 CTA-u/ml and a SK-concentration of 7–16 u/ml were recorded during streptokinase infusion. Plasminogen values averaged 0.25%, independent of the amount of streptokinase infused. Each drop in streptokinase was accompanied by a drop in activator during the infusion, and each rise in streptokinase by a rise in activator. There was a strong correlation between streptokinase and activator concentrations in that, on the average, 1 u streptokinase equalled 8.4 CTA-u/ml activator (correlation coefficient r = 0.9). It is concluded that the activator concentration in the plasma of patients undergoing fibrinolytic treatment can easily be adjusted by regulating the hourly streptokinase influx.

* Part I and II see this journal (1973) 30, 2, p. 381 and 393.


 
  • References

  • 1 Auel H, Martin M. 1974; Plasminogengehalt eines im Handel befindlichen Rinderfibrinogens. Zeitschrift für Klinische Chemie und Klinische Biochemie 12: 385.
  • 2 Heimburger N, Schwick H. G. 1971 Beitrag zur Charakterisierung des durch Streptokinase induzierten Aktivators Arzneimittel-Forsch. 21. 1439.
  • 3 Lassen M. 1952; Heat denaturisation of plasminogen in the fibrin plate method. Acta physica scandinavica 27: 371.
  • 4 Ling C. M, Summaria L, Robbins K. C. 1965; Mechanism of formation of bovine plasminogen activator from human plasmin. Journal of Biological Chemistry 240: 4213.
  • 5 Martin M. 1969; Semiquantitative Plasminogenbestimmung mit Hilfe des Thromboelastographen. Eine Methode zur Kontrolle der Streptokinasebehandlung. Thrombosis et Diathesis Haemorrhagica 22: 121.
  • 6 Martin M. 1973; a Studies on activator formation in human plasma. I. Experimental studies. Thrombosis et Diathesis Haemorrhagica 30: 381.
  • 7 Martin M. 1973; b Studies on activator formation in human plasma. II. Quantitative activator plasminogen measurements during continuous and intermittent streptokinase infusion. Thrombosis et Diathesis Haemorrhagica 30: 393.
  • 8 Martin M. 1974; Indirect measurement of streptokinase in the plasma of patients undergoing fibrinolytic treatment. Thrombosis et Diathesis Haemorrhagica 32: 633.
  • 9 Martin M. 1976; On the Reliability of Plasminogen Measurement Employing the Pro activai or-Activator Converting Method. Thrombos. Haemostas. (Stuttgart) 36: 551.
  • 10 Martin M, Schoop W, Zeitler E. 1970; Streptokinase in chronic arterial occlusive disease. Journal of the American medical Association 211: 1169.
  • 11 de Renzo E. C, Boggiano E, Barg W. F, Buck F. F. 1967; Interaction of streptokinase and human plasminogen. IV. Further gel electrophoretic studies on the combination of streptokinase with human plasminogen or human plasmin. Journal of Biological Chemistry 242: 2428.
  • 12 Robbins K. C, Summaria L, Elwyn D, Barlow E. H. 1965; Further studies on purification of human plasminogen and plasmin. Journal of Biological Chemistry 240: 541.
  • 13 Schwick H. G. 1967. Biochemie der Fibrinolyse, 26. In: Künzer W, Winckelmann G, Walther C. H. (Eds.): Biologie des Plasmins; Purpura Schönlein-Henoch; Erythrozytäre Gerinnungsaktivität. F. K. Schattauer Verlag; Stuttgart:
  • 14 Summaria L, Arzadon L, Bernabe P, Robbins K. C. 1974; The interaction of streptokinase with human, cat, dog, and rabbit plasminogen. Journal of Biological Chemistry 248: 4760.
  • 15 Summaria L, Ling C, Grosskopf W. R, Robbins K. C. 1968; The active site of bovine plasminogen activator; interaction of streptokinase with human plasminogen and plasmin. Journal of Biological Chemistry 243: 149.
  • 16 Taylor F. B, Beisswenger J. G. 1973; Identification of modified streptokinase as the activator of bovine and human plasminogen. Journal of Biological Chemistry 248: 1127.
  • 17 Ts’Ao C. H, Kline D. L. 1969; Plasminogen activator formed by reaction of streptokinase with human plasminogen. Journal of Applied Physiology 26: 634.